AGM/EGMApr 27, 2026, 04:54 PM
IPSC 2026 Annual Meeting: Proposes 450M Authorized Shares
AI Summary
Century Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 11, 2026. Key proposals include the election of two Class II directors and the ratification of Ernst & Young LLP as the independent auditor. The company also seeks approval to increase its authorized common stock from 300 million to 450 million shares. Additionally, the filing highlighted recent corporate progress, including a $135 million investment and advancements in its clinical programs.
Key Highlights
- 2026 Annual Meeting of Stockholders to be held virtually on June 11, 2026.
- Proposes to increase authorized common stock from 300,000,000 to 450,000,000 shares.
- Stockholders to vote on election of Alessandro Riva, M.D. and Han Lee, Ph.D., M.B.A. as Class II directors.
- Ratification of Ernst & Young LLP as independent registered public accounting firm for 2026.
- Timothy Walbert will not stand for re-election, reducing the Board to 6 members.
- Secured approximately $135 million in gross proceeds from a securities purchase agreement in January 2026.
- Advancing CNTY-813 and CNTY-308 programs towards IND submissions as early as 2026.
- Prioritizing clinical development of CNTY-101 in CARAMEL Phase 1/2 trial.